Joshua Barnard
Myasthenia gravis is a rare chronic autoimmune disease. It is currently a cureless antibody-mediated autoimmune disorder characterized by generalized voluntary skeletal muscle weakness. The root of the weakness is a flaw at the neuromuscular junction level, in which autoimmune antibodies obstruct the receptors accountable for commencing muscular contraction. The literal meaning of myasthenia gravis from its Latin and Greek etymological origins is 'grave muscle weakness'. Luckily, developments in modern medicine have resulted in a decline of the truly 'grave' consequences for those inflicted but, without a cure, the gravity encircling the disease remains. 3
